Paul Tudor Jones Denali Therapeutics Inc. Transaction History

Tudor Investment Corp Et Al

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$14.96 - $23.22 $196,394 - $304,832	-13,128 Reduced 18.32%	58,523 $1.36 Million
Q1 2024 May 15, 2024	BUY	$15.83 - $23.35 $1.13 Million - $1.67 Million	71,651 New	71,651 $1.47 Million
Q3 2023 Nov 15, 2023	BUY	$20.63 - $30.17 $866,872 - $1.27 Million	42,020 New	42,020 $866,000
Q1 2023 May 15, 2023	BUY	$21.91 - $32.67 $118,642 - $176,908	5,415 Added 10.84%	55,346 $1.28 Million
Q4 2022 Feb 14, 2023	BUY	$26.28 - $33.92 $1.31 Million - $1.69 Million	49,931 New	49,931 $1.39 Million
Q2 2022 Aug 15, 2022	BUY	$20.88 - $35.19 $343,768 - $579,368	16,464 New	16,464 $485,000
Q2 2021 Aug 16, 2021	SELL	$50.3 - $78.44 $1.97 Million - $3.07 Million	-39,106 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$53.8 - $81.53 $2.1 Million - $3.19 Million	39,106 New	39,106 $2.23 Million
Q3 2020 Nov 16, 2020	SELL	$23.13 - $38.84 $877,228 - $1.47 Million	-37,926 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$16.01 - $28.82 $607,195 - $1.09 Million	37,926 New	37,926 $917,000

241

121M

80K

36.8K

Ticker DNLI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 134,174,000
Market Cap $2.78B
Description
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...

Get notified when there are updates to the investment portfolio of Tudor Investment Corp Et Al, based on Form 13F filings with the SEC.

Stay updated on Tudor Investment Corp Et Al and Paul Tudor Jones with notifications on news.